EGFR and lung carcinoma: Several large-scale, Phase III clinical trials have demonstrated better clinical outcomes in patients with lung cancer harboring susceptible epidermal growth factor receptor (EGFR) mutations who were treated with tyrosine kinase inhibitors (TKIs), including improvements in overall response rate (ORR), progression free survival (PFS), and quality of life, compared with those receiving platinum-based chemotherapy [2,3,4,5].